The Global Ophthalmic Drugs Market will reach $22.5bn in 2015 says new Visiongain report

LONDON - Sept. 22, 2015 - PRLog -- PRESS RELEASE: “THE GLOBAL OPHTHALMIC DRUGS MARKET WILL REACH $22.5BN IN 2015 ACCORDING TO NEW VISIONGAIN REPORT”

LONDON, UK, 3^rd of July 2015: A new report by visiongain calculates that the global ophthalmic drugs market will reach $22.5bn in 2015 with revenues showing growth to 2025. These revenue forecasts and others appear in visiongain’s latest report Ophthalmic Drugs Market Forecast 2015-2025: Prospects for Leading Companies in Dry Eye, Glaucoma, Retinal Disorders, Allergic, Inflammatory & Infective Drugs. Visiongain is a leading market intelligence company based in London, UK.

Although a large portion of the revenue for ophthalmic drugs is currently dominated by a handful of leading companies, the market provides great opportunities for innovative players looking to enter into the market. Increasing demand for ophthalmic treatments, coupled with the rising level of diagnosis within the various market segments, will contribute to market growth over the coming decade. With some of the leading drugs within the market facing patent expiry in the major markets over the next few years, we expect generic competition to intensify. However, despite generic drug penetration, the market for ophthalmic drugs is a growing one with multiple products in various stages of development due to enter the market over the next decade.

Moses Akintomide-Akinwamide, a senior pharmaceutical and medical technology market analyst at Visiongain explains: “The ophthalmic drugs market has faced generic competition over the last few years, particularly for some of the leading products within the market. Despite this, the market has experienced growth with a high level of activities and multiple products in various stages of development targeting various ophthalmic indications. We expect the global ageing population and the expected boom in the incidence of ophthalmic conditions to contribute to growth in the ophthalmic drugs market over the next ten years. The rise of novel technologies such as gene therapies and RNA interference technologies for ophthalmic indications will couple with improving support for reimbursement and payment approvals to drive growth within the ophthalmic drugs market. However, the rising cost of R&D and difficulties with patient adherence may act to hinder growth within the market.”

Visiongain’s report provides revenue forecasts to 2025 for the global ophthalmic drugs market and its leading regional and national markets. It forecasts sales in the US, EU5 (Germany, Spain, Italy, UK, and France), India, Japan, China, Brazil, Russia, and Mexico. The report also forecasts sales for individual segments of the ophthalmic drugs market. These include the glaucoma drugs, retinal disorder drugs, allergic, infective and inflammatory drugs and dry eye drugs segments of the market. Analysis and forecasts for key marketed products in each of these segments are provided together with profiles, analyses, and forecasts of products in the development pipeline.

Analyses and evaluation of historical revenue and business operations of 9 leading companies within the market are also provided together with evaluation of their future potential. The ophthalmic drug revenues for these companies are also forecasted from 2015 to 2025. The report includes analyses of strengths, weaknesses, opportunities, and threats to the market, as well as porter’s five force analyses examining the powers of suppliers and buyers, the threat of substitutes and new entrants, and the rivalry amongst competitors in the market. Transcript of interviews with key opinion leaders in the industry sharing their views on current market trends and the unmet needs in the market are also included in the report.

Ophthalmic Drugs Market Forecast 2015-2025: Prospects for Leading Companies in Dry Eye, Glaucoma, Retinal Disorders, Allergic, Inflammatory & Infective Drugs adds to visiongain’s extensive range of analytical reports on industries and markets in healthcare.

For an executive summary please contact:
Email: Sara Peerun on sara.peerun@visiongainglobal.com

Tel: +44 (0) 20 7336 6100

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain

Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. From its head office in London, UK, visiongain produces a range of newsletters, business reports and e-zines covering current affairs and market trends in the Energy, Telecoms, Pharmaceutical, Defence, and Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional who needs independent, high quality, original analyses to inform their strategic decisions.